First-half 2026 sales grew 3% to €5.1m, driven by U.S. expansion and new surgeon adoption, despite a temporary setback from a key surgeon's absence. Cash position strengthened to €7.0m after a capital increase, supporting ongoing R&D and U.S. growth plans.Original document: S.M.A.I.O S.A. [ALSMA] E…
First-half 2026 sales grew 3% to €5.1m, driven by U.S. expansion and new surgeon adoption, despite a temporary setback from a key surgeon's absence. Cash position strengthened to €7.0m after a capital increase, supporting ongoing R&D and U.S. growth plans.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
